SlideShare a Scribd company logo
Exploring stakeholders’
views in the context of
collaborative, public health
research:
a mixed methods
approach
Teresa Jones on behalf of
the EQUIPT consortium
Please treat this presentation as
confidential as the work is still in
progress.
Overview
• Summary
• Background to the EQUIPT project
Aims of the UK mixed methods study
• Methods used
• Results – Qualitative & Quantitative
• What would we have missed by not using a
mixed methods approach?
• Conclusions
08 October 2015 T Jones Brunel University London 2
Summary
EQUIPT - The development of a viable, practical, decision-support
aid for use by decision makers across five European countries and
investigation of its transferability beyond those countries. The
inclusion of stakeholders’ views is considered to be a very
important aspect of the project.
Mixed methods study – to explore the additional information
obtained by including both quantitative and qualitative findings
from the UK stakeholder interviews
Funding: We have received funding from the European Community’s
Seventh Framework Programme under grant agreement No. 602270
(EQUIPT)
Ethics approval was received from Brunel University London Research
Ethics Committee
Background:
the EQUIPT project
• Development of a decision-support aid to
inform decisions on tobacco control spending
• For use initially in five European countries –
Germany, Hungary, Netherlands, Spain & UK
• To investigate the transferability of economic
evaluations beyond those five countries to
other Central and Eastern European countries
08 October 2015 4
Background:
aims of the mixed methods study
• To investigate the UK stakeholders’ needs for, and
views of, the proposed decision aid
• To conduct a quantitative analysis to provide the
overall picture of stakeholders’ perspectives and
also those of the UK stakeholders
• To collect qualitative data to help understand the
context for UK stakeholders
• Merging of results to provide enriched detail to
help understanding and enable creation of more
effective, country specific, bespoke decision aid.
08 October 2015 5
Method
08 October 2015 6
Quantitative & Qualitative data
collection via semi-structured face to
face interview
Quantitative data analysis Qualitative data analysis
Quantitative results Qualitative results
Merge results
Excel
SPSS
Coding
Excel
Interpretation
Double Data entry
Excel
Transcription of
audio files
Methods (1)
• Introduction of stakeholders to decision aid via
custom-built video
• Collection of views via questionnaire survey
• Countries: Germany, Hungary, Netherlands, Spain
& UK
• Stakeholders (purposive sample):
– decision makers;
– purchasers of services/pharma products;
– professionals/service deliverers;
– evidence generators;
– advocates of health promotion
08 October 2015 7
Method (2):
Questionnaire survey
• Specifically developed by EQUIPT team
members from all 5 countries
• Initially developed in English and then
translated into the language of each country
for the survey
• Conducted generally face to face, otherwise
by Skype or telephone
• Conducted by native speaker in each country
08 October 2015 8
Method (3):
Questionnaire survey(contd)
Question types
Quantitative
• 7-point Likert scale
(1=strongly disagree,
7=strongly agree)
08 October 2015 9
Survey method
• Interviewee’s place of
work
• Face to face
• Paper based
• Audio recorded
Qualitative
• Open questions at the
end of each section
Method (4):
Questionnaire survey (contd)
Questions included:
• Basic knowledge in health economics
• Needs assessment
• Risk perception
• Advantages & disadvantages of the decision aid
• Social support
• Self-efficacy
• Intention to use the decision aid
• Availability of smoking cessation interventions
08 October 2015 10
Method (5):
Data collection
Quantitative
• Total for 5 countries & the UK
• Double data-entry – Excel
• Analysis – SPSS
Qualitative
• The UK
• Transcription of UK audio recordings - Word
• Transfer of relevant text extracts - Excel
08 October 2015 11
Results (1):
Quantitative - Stakeholders
Total (5 countries) UK
Number of stakeholders 93 14
Role of stakeholders
- Decision makers 29 9
- Purchasers of
services/pharma
7 2
-Professional/service
providers
18 1
- Evidence generators 15 1
- Advocates of health
promotion
14 1
Intenders 81% 79%
08 October 2015 12
EQUIPT WP1 stakeholder interview data
Results (2)
Q1a – Who would support you in using the Tobacco
ROI tool?
Quantitative (7-point Likert scale)
Total (5 countries) UK
Overall score: mean(SD) 5.26(1.98) 6.26(2.09)
Intenders: mean (SD) *5.53(0.92) 6.30(1.48)
Non-intenders (SD) *3.28(1.30) 6.08(1.08)
08 October 2015 13
*statistically significant difference
EQUIPT WP1 stakeholder interview data
Results (2)
Q1b – Who else would support you in using the
Tobacco ROI tool?
Qualitative (open question)
08 October 2015 14
Government organisations:
• NHS;
• NICE;
• local authority directors of public
health;
• local politicians;
• local authority elected members;
• Local Government Association ;
health service mangers;
• health & social, care board
Research:
• Wider research community;
Voluntary/advocacy:
• advocacy organisations;
• ASH;
• voluntary sector;
• Smoke Free board
Other:
• some employer organisations eg
CBI, Federations of Small
Businesses;
• the public;
• an education setting;
• patient interest groups;
• patient client organisations
Results (3)
Q2a – I would encounter resistance using the
Tobacco ROI tool
Quantitative (7-point Likert scale)
Total (5 countries) UK
Overall score: mean(SD) 2.93(2.08) 2.92(2.27)
Intenders: mean (SD) 2.85(2.06) 3.18(2.32)
Non-intenders (SD) 3.53(2.00) 1.50(0.71)
08 October 2015 15
EQUIPT WP1 stakeholder interview data
Results (3)
Q2b – Who else would not support you in using
the Tobacco ROI tool?
Qualitative (open question)
08 October 2015 16
Government organisation:
• local government associations;
• NHS beyond public health;
• people with other health priorities
eg obesity or alcohol;
• those with commissioning
priorities;
• some council members concerned
about the nanny state;
• some public health staff who are
more qualitatively stronger;
• possibly too much based on
numbers and costs for the public
health arena
Others:
• Retailers;
• licensed traders;
• smokers
Results (4)
Q3a – How confident are you about using
the Tobacco ROI tool?
Quantitative (7-point Likert scale)
Total (5 countries) UK
Overall score: mean(SD) 5.28(1.98) 5.42(1.53)
Intenders: mean (SD) 5.33(0.80) 5.48(1.47)
Non-intenders (SD) 5.11(0.71) 5.19(1.47)
08 October 2015 17
EQUIPT WP1 stakeholder interview data
Results (4)
Q3b– What other difficulties would using such a
tool have for you?
Qualitative (open question)
08 October 2015 18
Current model:
• details of how the modelling has
been put together;
• data entry;
• confidence in and access to the
service level data;
• mismatch of data;
• clarity about the underlying data
and processing;
Updating:
• certainty that the most up to
date data is used;
• inclusion of new intervention
effects;
• capacity for the inclusion of local
data;
• introduction of e-cigarettes;
Other:
• Time;
• relevance to my role;
• a contact;
• targeting of a subset of the
population
What would we have missed by not
using a mixed methods approach?
Quantitative only
• Specific details on support from
organisations/groups
• Some organisations have been listed as
providing support and also resistance
• Specific detail on concerns about data quality,
updating of the decision aid, etc.
08 October 2015 19
What would we have missed by not
using a mixed methods approach?
Qualitative only
• Opinions from a broader group
• Non-intenders (all 5 countries) had less support
• But no significant difference in the level of
resistance between intenders/non-intenders
• Overall and in the UK, stakeholders were
confident about using the decision aid
• No significant difference between intenders/non-
intenders
08 October 2015 20
Preliminary conclusions
Mixed methods analysis:
• Beneficial to understanding the variations in
contexts & needs of stakeholders within UK
• Provides comparisons of stakeholder views
across 5 countries
• Enables development of a more effective aid
• Provides valuable information for
transferability
08 October 2015 21
Next steps
• Further integration of UK data
• Potentially explore data for Germany, Hungary,
Netherlands and Spain using similar methods
• Combination of data from all 5 countries to
identify similarities and differences
• Use combined data to further inform
development of the decision aid
08 October 2015 22

More Related Content

What's hot

Digital Primary Care
Digital Primary CareDigital Primary Care
Digital Primary Care
NHS England
 
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Office of Health Economics
 
The world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflectionThe world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflection
TGA Australia
 
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA
 
Survey of Early adopter steering committee members
Survey of Early adopter steering committee members Survey of Early adopter steering committee members
Survey of Early adopter steering committee members
Nuffield Trust
 
David Waller Interoperability Engagement Lead, NHS England
David Waller Interoperability Engagement Lead, NHS EnglandDavid Waller Interoperability Engagement Lead, NHS England
David Waller Interoperability Engagement Lead, NHS England
HIMSS UK
 
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation FundBenefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation FundPM Society
 
Anita nwachuku policy paper outline
Anita nwachuku policy paper outlineAnita nwachuku policy paper outline
Anita nwachuku policy paper outlineCharlene Quinn
 
Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014
Nuffield Trust
 
GPs' view of integration in North West London
GPs' view of integration in North West London GPs' view of integration in North West London
GPs' view of integration in North West London
Nuffield Trust
 
Joint Working workshop
Joint Working workshopJoint Working workshop
Joint Working workshopPM Society
 
CBA on reference laboratories human pathogens
CBA on reference laboratories human pathogensCBA on reference laboratories human pathogens
CBA on reference laboratories human pathogens
European Center for Disease Prevention and Control (ECDC)
 
Planning for life after the LSP Contracts
Planning for life after the LSP ContractsPlanning for life after the LSP Contracts
Planning for life after the LSP Contracts
The Health and Social Care Information Centre
 
Costing HIV testing Services Understand and Using Data for decision making
Costing HIV testing Services Understand and Using Data for decision makingCosting HIV testing Services Understand and Using Data for decision making
Costing HIV testing Services Understand and Using Data for decision making
Carmen Figueroa
 
Transforming General Practice through Technology
Transforming General Practice through TechnologyTransforming General Practice through Technology
Transforming General Practice through Technology
NHS England
 
The Digital Opportunity for Primary Care
The Digital Opportunity for Primary Care The Digital Opportunity for Primary Care
The Digital Opportunity for Primary Care
HIMSS UK
 
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Office of Health Economics
 
The Role of Technology in Transforming Primary Care
The Role of Technology in Transforming Primary CareThe Role of Technology in Transforming Primary Care
The Role of Technology in Transforming Primary Care
NHS England
 
Alpha One Conference - IPPOSI
Alpha One Conference - IPPOSIAlpha One Conference - IPPOSI
Alpha One Conference - IPPOSI
ipposi
 
MoH Presentation May 2015
MoH Presentation May 2015MoH Presentation May 2015
MoH Presentation May 2015
George Gray
 

What's hot (20)

Digital Primary Care
Digital Primary CareDigital Primary Care
Digital Primary Care
 
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
 
The world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflectionThe world of Regulatory convergence: an Australian reflection
The world of Regulatory convergence: an Australian reflection
 
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
 
Survey of Early adopter steering committee members
Survey of Early adopter steering committee members Survey of Early adopter steering committee members
Survey of Early adopter steering committee members
 
David Waller Interoperability Engagement Lead, NHS England
David Waller Interoperability Engagement Lead, NHS EnglandDavid Waller Interoperability Engagement Lead, NHS England
David Waller Interoperability Engagement Lead, NHS England
 
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation FundBenefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
 
Anita nwachuku policy paper outline
Anita nwachuku policy paper outlineAnita nwachuku policy paper outline
Anita nwachuku policy paper outline
 
Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014
 
GPs' view of integration in North West London
GPs' view of integration in North West London GPs' view of integration in North West London
GPs' view of integration in North West London
 
Joint Working workshop
Joint Working workshopJoint Working workshop
Joint Working workshop
 
CBA on reference laboratories human pathogens
CBA on reference laboratories human pathogensCBA on reference laboratories human pathogens
CBA on reference laboratories human pathogens
 
Planning for life after the LSP Contracts
Planning for life after the LSP ContractsPlanning for life after the LSP Contracts
Planning for life after the LSP Contracts
 
Costing HIV testing Services Understand and Using Data for decision making
Costing HIV testing Services Understand and Using Data for decision makingCosting HIV testing Services Understand and Using Data for decision making
Costing HIV testing Services Understand and Using Data for decision making
 
Transforming General Practice through Technology
Transforming General Practice through TechnologyTransforming General Practice through Technology
Transforming General Practice through Technology
 
The Digital Opportunity for Primary Care
The Digital Opportunity for Primary Care The Digital Opportunity for Primary Care
The Digital Opportunity for Primary Care
 
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
 
The Role of Technology in Transforming Primary Care
The Role of Technology in Transforming Primary CareThe Role of Technology in Transforming Primary Care
The Role of Technology in Transforming Primary Care
 
Alpha One Conference - IPPOSI
Alpha One Conference - IPPOSIAlpha One Conference - IPPOSI
Alpha One Conference - IPPOSI
 
MoH Presentation May 2015
MoH Presentation May 2015MoH Presentation May 2015
MoH Presentation May 2015
 

Similar to Exploring stakeholders' views in the context of collaborative, public health research: A mixed methods approach

Exploring the stakeholders' views in the context of collaborative, public hea...
Exploring the stakeholders' views in the context of collaborative, public hea...Exploring the stakeholders' views in the context of collaborative, public hea...
Exploring the stakeholders' views in the context of collaborative, public hea...
Gemma Derrick
 
Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...
Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...
Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...
UKFacultyPublicHealth
 
NCCMT webinar - Policy Readiness Tool (Part 1)
NCCMT webinar - Policy Readiness Tool (Part 1)NCCMT webinar - Policy Readiness Tool (Part 1)
NCCMT webinar - Policy Readiness Tool (Part 1)
The National Collaborating Centre for Methods and Tools
 
MeTA and data disclosure
MeTA and data disclosureMeTA and data disclosure
MeTA and data disclosure
MeTApresents
 
Implementation of Electronic Screening & Clinical Support into General Outpat...
Implementation of Electronic Screening & Clinical Support into General Outpat...Implementation of Electronic Screening & Clinical Support into General Outpat...
Implementation of Electronic Screening & Clinical Support into General Outpat...
chshanah
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Dr. Tayaba Khan
 
Drive communication plan and debate - Sharon McHale & Riia Järvenpää
Drive communication plan and debate - Sharon McHale & Riia JärvenpääDrive communication plan and debate - Sharon McHale & Riia Järvenpää
Drive communication plan and debate - Sharon McHale & Riia Järvenpää
DRIVE research
 
Shanahan tdg sig meeting 3 15-11 v2.1
Shanahan tdg sig meeting 3 15-11 v2.1Shanahan tdg sig meeting 3 15-11 v2.1
Shanahan tdg sig meeting 3 15-11 v2.1BU School of Medicine
 
Jornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy CliffordJornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy Clifford
Instituto Aragonés de Ciencias de la Salud - IACS
 
Feasibility analyses and development of ‘best practice’ criteria
Feasibility analyses and development of ‘best practice’ criteria Feasibility analyses and development of ‘best practice’ criteria
Feasibility analyses and development of ‘best practice’ criteria
Forest Research
 
EU Draft mHealth App Assessment Guidelines
EU Draft mHealth App Assessment GuidelinesEU Draft mHealth App Assessment Guidelines
EU Draft mHealth App Assessment Guidelines
3GDR
 
ILF Chronic Oedema Outcomes Project
ILF Chronic Oedema Outcomes ProjectILF Chronic Oedema Outcomes Project
ILF Chronic Oedema Outcomes Project
Mary Fickling
 
dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020
dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020
dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020
dkNET
 
DELSA/GOV 3rd Health meeting - Barbara UBALDI
DELSA/GOV 3rd Health meeting - Barbara UBALDIDELSA/GOV 3rd Health meeting - Barbara UBALDI
DELSA/GOV 3rd Health meeting - Barbara UBALDI
OECD Governance
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
Office of Health Economics
 
Health System Efficiency and Sustainability in Australia, Canada, France, Ger...
Health System Efficiency and Sustainability in Australia, Canada, France, Ger...Health System Efficiency and Sustainability in Australia, Canada, France, Ger...
Health System Efficiency and Sustainability in Australia, Canada, France, Ger...
Office of Health Economics
 
How to use the LTC year of care commissioning simulation tool webinar
How to use the LTC year of care commissioning simulation tool webinarHow to use the LTC year of care commissioning simulation tool webinar
How to use the LTC year of care commissioning simulation tool webinar
NHS Improving Quality
 
Paying for performance to improve the delivery of health interventions in LMICs
Paying for performance to improve the delivery of health interventions in LMICsPaying for performance to improve the delivery of health interventions in LMICs
Paying for performance to improve the delivery of health interventions in LMICs
ReBUILD for Resilience
 
Working together in health information for Health and Well-being in Europe
Working together in health information for Health and Well-being in EuropeWorking together in health information for Health and Well-being in Europe
Working together in health information for Health and Well-being in Europe
WHO Regional Office for Europe
 
Nicholas Mays: More than Methods
Nicholas Mays: More than Methods Nicholas Mays: More than Methods
Nicholas Mays: More than Methods
Nuffield Trust
 

Similar to Exploring stakeholders' views in the context of collaborative, public health research: A mixed methods approach (20)

Exploring the stakeholders' views in the context of collaborative, public hea...
Exploring the stakeholders' views in the context of collaborative, public hea...Exploring the stakeholders' views in the context of collaborative, public hea...
Exploring the stakeholders' views in the context of collaborative, public hea...
 
Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...
Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...
Using Stakeholder Engagement to Inform the Development and Expansion, and Inc...
 
NCCMT webinar - Policy Readiness Tool (Part 1)
NCCMT webinar - Policy Readiness Tool (Part 1)NCCMT webinar - Policy Readiness Tool (Part 1)
NCCMT webinar - Policy Readiness Tool (Part 1)
 
MeTA and data disclosure
MeTA and data disclosureMeTA and data disclosure
MeTA and data disclosure
 
Implementation of Electronic Screening & Clinical Support into General Outpat...
Implementation of Electronic Screening & Clinical Support into General Outpat...Implementation of Electronic Screening & Clinical Support into General Outpat...
Implementation of Electronic Screening & Clinical Support into General Outpat...
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
 
Drive communication plan and debate - Sharon McHale & Riia Järvenpää
Drive communication plan and debate - Sharon McHale & Riia JärvenpääDrive communication plan and debate - Sharon McHale & Riia Järvenpää
Drive communication plan and debate - Sharon McHale & Riia Järvenpää
 
Shanahan tdg sig meeting 3 15-11 v2.1
Shanahan tdg sig meeting 3 15-11 v2.1Shanahan tdg sig meeting 3 15-11 v2.1
Shanahan tdg sig meeting 3 15-11 v2.1
 
Jornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy CliffordJornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy Clifford
 
Feasibility analyses and development of ‘best practice’ criteria
Feasibility analyses and development of ‘best practice’ criteria Feasibility analyses and development of ‘best practice’ criteria
Feasibility analyses and development of ‘best practice’ criteria
 
EU Draft mHealth App Assessment Guidelines
EU Draft mHealth App Assessment GuidelinesEU Draft mHealth App Assessment Guidelines
EU Draft mHealth App Assessment Guidelines
 
ILF Chronic Oedema Outcomes Project
ILF Chronic Oedema Outcomes ProjectILF Chronic Oedema Outcomes Project
ILF Chronic Oedema Outcomes Project
 
dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020
dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020
dkNET Webinar - Vivli: A Global Clinical Trials Data Sharing Platform 12/11/2020
 
DELSA/GOV 3rd Health meeting - Barbara UBALDI
DELSA/GOV 3rd Health meeting - Barbara UBALDIDELSA/GOV 3rd Health meeting - Barbara UBALDI
DELSA/GOV 3rd Health meeting - Barbara UBALDI
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
 
Health System Efficiency and Sustainability in Australia, Canada, France, Ger...
Health System Efficiency and Sustainability in Australia, Canada, France, Ger...Health System Efficiency and Sustainability in Australia, Canada, France, Ger...
Health System Efficiency and Sustainability in Australia, Canada, France, Ger...
 
How to use the LTC year of care commissioning simulation tool webinar
How to use the LTC year of care commissioning simulation tool webinarHow to use the LTC year of care commissioning simulation tool webinar
How to use the LTC year of care commissioning simulation tool webinar
 
Paying for performance to improve the delivery of health interventions in LMICs
Paying for performance to improve the delivery of health interventions in LMICsPaying for performance to improve the delivery of health interventions in LMICs
Paying for performance to improve the delivery of health interventions in LMICs
 
Working together in health information for Health and Well-being in Europe
Working together in health information for Health and Well-being in EuropeWorking together in health information for Health and Well-being in Europe
Working together in health information for Health and Well-being in Europe
 
Nicholas Mays: More than Methods
Nicholas Mays: More than Methods Nicholas Mays: More than Methods
Nicholas Mays: More than Methods
 

More from Gemma Derrick

(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...
(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...
(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...
Gemma Derrick
 
Validity and Reliability of Qualitative Assessments based on self-reported st...
Validity and Reliability of Qualitative Assessments based on self-reported st...Validity and Reliability of Qualitative Assessments based on self-reported st...
Validity and Reliability of Qualitative Assessments based on self-reported st...
Gemma Derrick
 
Case study narratives
Case study narrativesCase study narratives
Case study narratives
Gemma Derrick
 
QMM2015 Welcome
QMM2015 WelcomeQMM2015 Welcome
QMM2015 Welcome
Gemma Derrick
 
Involving end users in research proposal evaluation: A case study with the Du...
Involving end users in research proposal evaluation: A case study with the Du...Involving end users in research proposal evaluation: A case study with the Du...
Involving end users in research proposal evaluation: A case study with the Du...
Gemma Derrick
 
The in-vitro approach: Qualitative methodology to explore panel based peer re...
The in-vitro approach: Qualitative methodology to explore panel based peer re...The in-vitro approach: Qualitative methodology to explore panel based peer re...
The in-vitro approach: Qualitative methodology to explore panel based peer re...
Gemma Derrick
 
Multiplying method: Ethnography and the reconceptualization of evaluation stu...
Multiplying method: Ethnography and the reconceptualization of evaluation stu...Multiplying method: Ethnography and the reconceptualization of evaluation stu...
Multiplying method: Ethnography and the reconceptualization of evaluation stu...
Gemma Derrick
 
Taking the measure of quality: Mixed methods or mixed feelings?
Taking the measure of quality: Mixed methods or mixed feelings?Taking the measure of quality: Mixed methods or mixed feelings?
Taking the measure of quality: Mixed methods or mixed feelings?
Gemma Derrick
 
Focus! A discussion about the use of focus groups as a method
Focus! A discussion about the use of focus groups as a methodFocus! A discussion about the use of focus groups as a method
Focus! A discussion about the use of focus groups as a method
Gemma Derrick
 
Career development after being awarded by an early personal grant
Career development after being awarded by an early personal grantCareer development after being awarded by an early personal grant
Career development after being awarded by an early personal grant
Gemma Derrick
 
Rethinking the 'international' in the governance of science
Rethinking the 'international' in the governance of scienceRethinking the 'international' in the governance of science
Rethinking the 'international' in the governance of science
Gemma Derrick
 
Intentions and strategies for evaluating the societal impact of research: Ins...
Intentions and strategies for evaluating the societal impact of research: Ins...Intentions and strategies for evaluating the societal impact of research: Ins...
Intentions and strategies for evaluating the societal impact of research: Ins...
Gemma Derrick
 

More from Gemma Derrick (12)

(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...
(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...
(I Can't Get No) Saturation: A Simulation and Guidelines for Minimum Sample S...
 
Validity and Reliability of Qualitative Assessments based on self-reported st...
Validity and Reliability of Qualitative Assessments based on self-reported st...Validity and Reliability of Qualitative Assessments based on self-reported st...
Validity and Reliability of Qualitative Assessments based on self-reported st...
 
Case study narratives
Case study narrativesCase study narratives
Case study narratives
 
QMM2015 Welcome
QMM2015 WelcomeQMM2015 Welcome
QMM2015 Welcome
 
Involving end users in research proposal evaluation: A case study with the Du...
Involving end users in research proposal evaluation: A case study with the Du...Involving end users in research proposal evaluation: A case study with the Du...
Involving end users in research proposal evaluation: A case study with the Du...
 
The in-vitro approach: Qualitative methodology to explore panel based peer re...
The in-vitro approach: Qualitative methodology to explore panel based peer re...The in-vitro approach: Qualitative methodology to explore panel based peer re...
The in-vitro approach: Qualitative methodology to explore panel based peer re...
 
Multiplying method: Ethnography and the reconceptualization of evaluation stu...
Multiplying method: Ethnography and the reconceptualization of evaluation stu...Multiplying method: Ethnography and the reconceptualization of evaluation stu...
Multiplying method: Ethnography and the reconceptualization of evaluation stu...
 
Taking the measure of quality: Mixed methods or mixed feelings?
Taking the measure of quality: Mixed methods or mixed feelings?Taking the measure of quality: Mixed methods or mixed feelings?
Taking the measure of quality: Mixed methods or mixed feelings?
 
Focus! A discussion about the use of focus groups as a method
Focus! A discussion about the use of focus groups as a methodFocus! A discussion about the use of focus groups as a method
Focus! A discussion about the use of focus groups as a method
 
Career development after being awarded by an early personal grant
Career development after being awarded by an early personal grantCareer development after being awarded by an early personal grant
Career development after being awarded by an early personal grant
 
Rethinking the 'international' in the governance of science
Rethinking the 'international' in the governance of scienceRethinking the 'international' in the governance of science
Rethinking the 'international' in the governance of science
 
Intentions and strategies for evaluating the societal impact of research: Ins...
Intentions and strategies for evaluating the societal impact of research: Ins...Intentions and strategies for evaluating the societal impact of research: Ins...
Intentions and strategies for evaluating the societal impact of research: Ins...
 

Recently uploaded

PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATIONPRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
ChetanK57
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Sérgio Sacani
 
Citrus Greening Disease and its Management
Citrus Greening Disease and its ManagementCitrus Greening Disease and its Management
Citrus Greening Disease and its Management
subedisuryaofficial
 
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
muralinath2
 
Comparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebratesComparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebrates
sachin783648
 
insect morphology and physiology of insect
insect morphology and physiology of insectinsect morphology and physiology of insect
insect morphology and physiology of insect
anitaento25
 
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCINGRNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
AADYARAJPANDEY1
 
filosofia boliviana introducción jsjdjd.pptx
filosofia boliviana introducción jsjdjd.pptxfilosofia boliviana introducción jsjdjd.pptx
filosofia boliviana introducción jsjdjd.pptx
IvanMallco1
 
general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
IqrimaNabilatulhusni
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
AlaminAfendy1
 
Large scale production of streptomycin.pptx
Large scale production of streptomycin.pptxLarge scale production of streptomycin.pptx
Large scale production of streptomycin.pptx
Cherry
 
EY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptxEY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptx
AlguinaldoKong
 
Richard's entangled aventures in wonderland
Richard's entangled aventures in wonderlandRichard's entangled aventures in wonderland
Richard's entangled aventures in wonderland
Richard Gill
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
muralinath2
 
Viksit bharat till 2047 India@2047.pptx
Viksit bharat till 2047  India@2047.pptxViksit bharat till 2047  India@2047.pptx
Viksit bharat till 2047 India@2047.pptx
rakeshsharma20142015
 
justice-and-fairness-ethics with example
justice-and-fairness-ethics with examplejustice-and-fairness-ethics with example
justice-and-fairness-ethics with example
azzyixes
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
Lokesh Patil
 
Anemia_ different types_causes_ conditions
Anemia_ different types_causes_ conditionsAnemia_ different types_causes_ conditions
Anemia_ different types_causes_ conditions
muralinath2
 
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdfSCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SELF-EXPLANATORY
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
muralinath2
 

Recently uploaded (20)

PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATIONPRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
PRESENTATION ABOUT PRINCIPLE OF COSMATIC EVALUATION
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
 
Citrus Greening Disease and its Management
Citrus Greening Disease and its ManagementCitrus Greening Disease and its Management
Citrus Greening Disease and its Management
 
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
Circulatory system_ Laplace law. Ohms law.reynaults law,baro-chemo-receptors-...
 
Comparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebratesComparative structure of adrenal gland in vertebrates
Comparative structure of adrenal gland in vertebrates
 
insect morphology and physiology of insect
insect morphology and physiology of insectinsect morphology and physiology of insect
insect morphology and physiology of insect
 
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCINGRNA INTERFERENCE: UNRAVELING GENETIC SILENCING
RNA INTERFERENCE: UNRAVELING GENETIC SILENCING
 
filosofia boliviana introducción jsjdjd.pptx
filosofia boliviana introducción jsjdjd.pptxfilosofia boliviana introducción jsjdjd.pptx
filosofia boliviana introducción jsjdjd.pptx
 
general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
 
Large scale production of streptomycin.pptx
Large scale production of streptomycin.pptxLarge scale production of streptomycin.pptx
Large scale production of streptomycin.pptx
 
EY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptxEY - Supply Chain Services 2018_template.pptx
EY - Supply Chain Services 2018_template.pptx
 
Richard's entangled aventures in wonderland
Richard's entangled aventures in wonderlandRichard's entangled aventures in wonderland
Richard's entangled aventures in wonderland
 
platelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptxplatelets- lifespan -Clot retraction-disorders.pptx
platelets- lifespan -Clot retraction-disorders.pptx
 
Viksit bharat till 2047 India@2047.pptx
Viksit bharat till 2047  India@2047.pptxViksit bharat till 2047  India@2047.pptx
Viksit bharat till 2047 India@2047.pptx
 
justice-and-fairness-ethics with example
justice-and-fairness-ethics with examplejustice-and-fairness-ethics with example
justice-and-fairness-ethics with example
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
 
Anemia_ different types_causes_ conditions
Anemia_ different types_causes_ conditionsAnemia_ different types_causes_ conditions
Anemia_ different types_causes_ conditions
 
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdfSCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
 

Exploring stakeholders' views in the context of collaborative, public health research: A mixed methods approach

  • 1. Exploring stakeholders’ views in the context of collaborative, public health research: a mixed methods approach Teresa Jones on behalf of the EQUIPT consortium Please treat this presentation as confidential as the work is still in progress.
  • 2. Overview • Summary • Background to the EQUIPT project Aims of the UK mixed methods study • Methods used • Results – Qualitative & Quantitative • What would we have missed by not using a mixed methods approach? • Conclusions 08 October 2015 T Jones Brunel University London 2
  • 3. Summary EQUIPT - The development of a viable, practical, decision-support aid for use by decision makers across five European countries and investigation of its transferability beyond those countries. The inclusion of stakeholders’ views is considered to be a very important aspect of the project. Mixed methods study – to explore the additional information obtained by including both quantitative and qualitative findings from the UK stakeholder interviews Funding: We have received funding from the European Community’s Seventh Framework Programme under grant agreement No. 602270 (EQUIPT) Ethics approval was received from Brunel University London Research Ethics Committee
  • 4. Background: the EQUIPT project • Development of a decision-support aid to inform decisions on tobacco control spending • For use initially in five European countries – Germany, Hungary, Netherlands, Spain & UK • To investigate the transferability of economic evaluations beyond those five countries to other Central and Eastern European countries 08 October 2015 4
  • 5. Background: aims of the mixed methods study • To investigate the UK stakeholders’ needs for, and views of, the proposed decision aid • To conduct a quantitative analysis to provide the overall picture of stakeholders’ perspectives and also those of the UK stakeholders • To collect qualitative data to help understand the context for UK stakeholders • Merging of results to provide enriched detail to help understanding and enable creation of more effective, country specific, bespoke decision aid. 08 October 2015 5
  • 6. Method 08 October 2015 6 Quantitative & Qualitative data collection via semi-structured face to face interview Quantitative data analysis Qualitative data analysis Quantitative results Qualitative results Merge results Excel SPSS Coding Excel Interpretation Double Data entry Excel Transcription of audio files
  • 7. Methods (1) • Introduction of stakeholders to decision aid via custom-built video • Collection of views via questionnaire survey • Countries: Germany, Hungary, Netherlands, Spain & UK • Stakeholders (purposive sample): – decision makers; – purchasers of services/pharma products; – professionals/service deliverers; – evidence generators; – advocates of health promotion 08 October 2015 7
  • 8. Method (2): Questionnaire survey • Specifically developed by EQUIPT team members from all 5 countries • Initially developed in English and then translated into the language of each country for the survey • Conducted generally face to face, otherwise by Skype or telephone • Conducted by native speaker in each country 08 October 2015 8
  • 9. Method (3): Questionnaire survey(contd) Question types Quantitative • 7-point Likert scale (1=strongly disagree, 7=strongly agree) 08 October 2015 9 Survey method • Interviewee’s place of work • Face to face • Paper based • Audio recorded Qualitative • Open questions at the end of each section
  • 10. Method (4): Questionnaire survey (contd) Questions included: • Basic knowledge in health economics • Needs assessment • Risk perception • Advantages & disadvantages of the decision aid • Social support • Self-efficacy • Intention to use the decision aid • Availability of smoking cessation interventions 08 October 2015 10
  • 11. Method (5): Data collection Quantitative • Total for 5 countries & the UK • Double data-entry – Excel • Analysis – SPSS Qualitative • The UK • Transcription of UK audio recordings - Word • Transfer of relevant text extracts - Excel 08 October 2015 11
  • 12. Results (1): Quantitative - Stakeholders Total (5 countries) UK Number of stakeholders 93 14 Role of stakeholders - Decision makers 29 9 - Purchasers of services/pharma 7 2 -Professional/service providers 18 1 - Evidence generators 15 1 - Advocates of health promotion 14 1 Intenders 81% 79% 08 October 2015 12 EQUIPT WP1 stakeholder interview data
  • 13. Results (2) Q1a – Who would support you in using the Tobacco ROI tool? Quantitative (7-point Likert scale) Total (5 countries) UK Overall score: mean(SD) 5.26(1.98) 6.26(2.09) Intenders: mean (SD) *5.53(0.92) 6.30(1.48) Non-intenders (SD) *3.28(1.30) 6.08(1.08) 08 October 2015 13 *statistically significant difference EQUIPT WP1 stakeholder interview data
  • 14. Results (2) Q1b – Who else would support you in using the Tobacco ROI tool? Qualitative (open question) 08 October 2015 14 Government organisations: • NHS; • NICE; • local authority directors of public health; • local politicians; • local authority elected members; • Local Government Association ; health service mangers; • health & social, care board Research: • Wider research community; Voluntary/advocacy: • advocacy organisations; • ASH; • voluntary sector; • Smoke Free board Other: • some employer organisations eg CBI, Federations of Small Businesses; • the public; • an education setting; • patient interest groups; • patient client organisations
  • 15. Results (3) Q2a – I would encounter resistance using the Tobacco ROI tool Quantitative (7-point Likert scale) Total (5 countries) UK Overall score: mean(SD) 2.93(2.08) 2.92(2.27) Intenders: mean (SD) 2.85(2.06) 3.18(2.32) Non-intenders (SD) 3.53(2.00) 1.50(0.71) 08 October 2015 15 EQUIPT WP1 stakeholder interview data
  • 16. Results (3) Q2b – Who else would not support you in using the Tobacco ROI tool? Qualitative (open question) 08 October 2015 16 Government organisation: • local government associations; • NHS beyond public health; • people with other health priorities eg obesity or alcohol; • those with commissioning priorities; • some council members concerned about the nanny state; • some public health staff who are more qualitatively stronger; • possibly too much based on numbers and costs for the public health arena Others: • Retailers; • licensed traders; • smokers
  • 17. Results (4) Q3a – How confident are you about using the Tobacco ROI tool? Quantitative (7-point Likert scale) Total (5 countries) UK Overall score: mean(SD) 5.28(1.98) 5.42(1.53) Intenders: mean (SD) 5.33(0.80) 5.48(1.47) Non-intenders (SD) 5.11(0.71) 5.19(1.47) 08 October 2015 17 EQUIPT WP1 stakeholder interview data
  • 18. Results (4) Q3b– What other difficulties would using such a tool have for you? Qualitative (open question) 08 October 2015 18 Current model: • details of how the modelling has been put together; • data entry; • confidence in and access to the service level data; • mismatch of data; • clarity about the underlying data and processing; Updating: • certainty that the most up to date data is used; • inclusion of new intervention effects; • capacity for the inclusion of local data; • introduction of e-cigarettes; Other: • Time; • relevance to my role; • a contact; • targeting of a subset of the population
  • 19. What would we have missed by not using a mixed methods approach? Quantitative only • Specific details on support from organisations/groups • Some organisations have been listed as providing support and also resistance • Specific detail on concerns about data quality, updating of the decision aid, etc. 08 October 2015 19
  • 20. What would we have missed by not using a mixed methods approach? Qualitative only • Opinions from a broader group • Non-intenders (all 5 countries) had less support • But no significant difference in the level of resistance between intenders/non-intenders • Overall and in the UK, stakeholders were confident about using the decision aid • No significant difference between intenders/non- intenders 08 October 2015 20
  • 21. Preliminary conclusions Mixed methods analysis: • Beneficial to understanding the variations in contexts & needs of stakeholders within UK • Provides comparisons of stakeholder views across 5 countries • Enables development of a more effective aid • Provides valuable information for transferability 08 October 2015 21
  • 22. Next steps • Further integration of UK data • Potentially explore data for Germany, Hungary, Netherlands and Spain using similar methods • Combination of data from all 5 countries to identify similarities and differences • Use combined data to further inform development of the decision aid 08 October 2015 22